Company Presentation June 2011 Biotest AG 0

(1)

(2)

Disclaimer

•

This document contains forward-looking statements on overall economic

development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans,

estimates, forecasts and expectations of the company and thus are subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments.

•

The forward looking statements are only valid at the time of publication Biotest does

•

The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

(3)

Big Success for Biotest's Biotherapeutics:

Biotest and Abbott signed a

"Licence, Development and Commercialization

Licence, Development and Commercialization

Agreement"

to ensure the further development as well as later on production

and worldwide marketing and sales of BT-061

(4)

Biotest and Abbott Global Agreement towards BT-061

• Biotest receives upfront payment of USD 85 million

• Biotest will be eligible to milestone payments pending completion of certain development regulatory commercial and sales milestones

development, regulatory, commercial and sales milestones

• Total Potential Milestone Payments USD 395 million

• Total Deal Value: USD 480 million

• Biotest will receive royalty payments on net sales achieved outside Europe EU51)

• For Europe EU5 cost/profit split agreed

• Partnership Structure

• Joint development by Biotest and Abbott

• Biotest to co promote BT 061 in Germany France United Kingdom Italy Spain

• Biotest to co-promote BT-061 in Germany, France, United Kingdom, Italy, Spain

• Abbott will have exclusive global rights to commercialize BT-061 outside the EU5

• Biotest Pharmaceuticals Corp. to manufacture product for clinical trials

• Abbott and Biotest will share responsibility for commercial production

(5)

BT-061: Compound Specifics and Development Status

• Monoclonal antibody that activates regulatory T cells

• Humanization by CDR grafting

• Non-depleting

• Species specificity: binds only to a special epitope on h CD4

human CD4

• No activation of effector T cells

P i i ffi d f d f h II li i l

• Promising efficacy and safety data of phase II clinical trials in Rheumatoid Arthritis (RA) and Psoriasis (PS)

(6)

BT 061 H

th P t

ti l t M di ll Diff

ti t

i

BT-061 Has the Potential to Medically Differentiate via

Efficacy and Safety

G d f t fil ft t t t f 350 bj t

• Good safety profile after treatment of approx. 350 subjects

(7)

conventional anti CD4 mAbs

Unique Mode of Action of BT-061:

Comparison to Conventional CD4 mAbs

BT-061

non-depleting depleting

(e.g. HuMax-CD4*)

ADCC

conventional anti-CD4 mAbs

CDC ADCC Depletion +

+/

-Blockade of CD4 function required

-

+ Activation of Tregs

Activation of T helper cells

+

--

-Efficacy not sufficient

Doses required for clinical

efficacy (iv) 100 - 1000 mg iv

high efficacy already at 100-2000 fold lower

doses (0.5 - 2.5 mg iv) 50 - 500 mg iv

Efficacy not sufficient for clinical success in autoimmune disease

(8)

Market Environment in Rheumatoid Arthritis and

Psoriasis

(9)

Rheumatoid Arthritis Market:

1

Continuous Growth until 2014 Driven by Biologics

12

$)

TNF inhibitors Non-TNF (Biologics & NCE) Others

8 10 (bn US $

CAGR: 4.7%

6 8 et volume 4 Mark e 0 2 1 = MM7; 7 major markets

2009 2014 Source: Decision Resources 2011 NCE: new chemical entities

(10)

Largest Products in RA in 2010 in MM7

1

(bn US $)

Enbrel (Wyeth/Pfizer) Remicade (Centocor/J&J) Humira (Abbott) Orencia (BMS)

ENBREL (Pfizer/Amgen) HUMIRA (Abbott/Eisai)

REMICADE (Centocor/J&J/MSD) ORENCIA (BMS)

•

Abbott one of the major

0 6

Rituxan (Roche)_{MABthera (Roche)}

RITUXAN (Genentech/Biogen Idec)

j players

3.1

0.5

0.6

2.0

1.6

1 = MM7; 7 Major Markets

(11)

Rheumatoid Arthritis Product Sales Forecast for MM7

1

Patent Expiries after 2014 Generates Pressure on anti-TNFs

14

)

TNF inhibitors Non-TNF (Biologics & NCE)2 Others

10 12

(bn US $

)

• Patent expiries from

2014 onwards

• Price pressure from

6 8

t volume

• Price pressure from

Biosimilars expected

2 4 6 Marke t 0 2 1 = MM7; 7 Major Markets 2 = NCE: new chemical entities Source: Decision Resources 2011

(12)

Rheumatoid Arthritis Product Sales Forecast for MM7

1

Innovative Products Needed in Rheumatoid Arthritis

14

)

TNF inhibitors Non-TNF (Biologics & NCE)2 Others

10 12

(bn US $

)

• Patent expiries from

2014 onwards

• Price pressure from

6 8

t volume

• Price pressure from

Biosimilars expected

2 4 6 Marke t

High level of importance of

new innovative products:

t

i i

di l

d

0

2

_{• meet remaining medical need}

• keep high price on the basis

of medical differentiation

1 = MM7; 7 Major Markets 2 = NCE: new chemical entities Source: Decision Resources 2011

(13)

• Many candidates stopped within last two years due to lack of clear differentiation

Competitive Environment

y pp y

• Pipeline dominated by "me too" candidates

• Only few innovative products in development, but required to further improve patient safety

improve patient safety and efficacy Orencia Rituxan Actemra BT-061 (Biotest) Orencia Cimzia Golimumab (Centocor/J&J) TNF-Kinase Inhibitors

IL-17 Inhibitors

GAP

Remicade (Centocor/J&J) Humira (Abbott) Cimzia (UCB) TNF-Inhibitors IL-17 Inhibitors

IL-6 Inhibitors only few candidates in late-stage clinical d l t Enbrel (Wyeth/Pfizer) (Centocor/J&J) B-cell Inhibitors T cell Inhibitors development Approved Filed Phase III Phase II Phase I Pre-clinical Development stage

(14)

Biotest's Biotherapeutics portfolio

BT-061 BT-062 BT-063

Blockage of

immuno-regulatory cytokine with key role in pathogenesis of SLE Activated Tregs mediate

modulation of T effector cells Tumor-activated payload _{(TAP) technology}

Potential Indications

•

Systemic Lupus E th t (SLE) Potential Indications

•

Rheumatoid Arthritis

•

P i i Potential Indications

•

Multiple Myeloma

•

S lid t Erythematosus (SLE)

•

Oncology

•

Psoriasis

•

Other autoimmune diseases

(15)

Biotest : Future corporate structure

Biotest AG

Microbiological M i i Medical Biotherapeutics

Plasma Proteins _Monitoring

Diagnostics Biotherapeutics Plasma Proteins -Immunoglobu-lines Monoclonal Antibodies ("mAb"): Plasma Proteins

Sold to Bio-Rad Sold to Merck KGaA lines - Hyper-immuno-globulines - Clotting Factors Albumin - BT-061 - BT-062 - BT-063 - Albumin

Focus on Pharma Biotest will be a specialized pharmaceutical

company with focus on Plasma Proteins and company with focus on Plasma Proteins and Biotherapeutics

(16)

Biotest: a specialized pharmaceutical company

Biotest AG

Pharmaceuticals

Divisions

Plasma Proteins Extension into: • Clinical Development Biotherapeutics • USA • Spain • Brazil • new indications • Clinical Development ongoing • Production at BPC • New patents • License Agreement

• new products • License Agreement

Sales*: € 412.5 m R&D*: - € 27.9 m Sales*: € 0.0 m R&D*: - € 21.1 m EBIT*: € 73.4 m EBIT*: - € 21.7 m

*

FY 2010

(17)

Thank you

(18)

Contact

Investor Relations Biotest AG:

Dr. Monika Buttkereit

Head of Investor Relations

Phone: +49 (0) 6103 801 4406 Phone: +49 (0) 6103 - 801 -4406 Fax: +49 (0) 6103 - 801 -347